Johnson Amanda M, Loftus Edward V
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Expert Opin Biol Ther. 2024 Dec;24(12):1317-1327. doi: 10.1080/14712598.2024.2428311. Epub 2024 Nov 13.
Risankizumab (RZB) is a recombinant IgG humanized monoclonal antibody which selectively inhibits interleukin (IL)-23 though high-affinity binding of the p19 subunit. RZB was approved for use in Crohn's disease (CD) in 2022 and received regulatory approval for ulcerative colitis (UC) in the United States in June 2024.
We will examine currently available therapies for UC, provide an overview of the IL-23 pathway, discuss available trial data for RZB in UC, and comment on how RZB may fit into the current UC treatment paradigm and future directions in the field.
RZB appears to be an effective agent for inducing and maintaining remission in patients with both treatment-naïve and refractory UC, with a favorable safety profile. The selective blockade of IL-23 has demonstrated potential advantages in efficacy over combined IL-12/23 inhibition for other disease states like CD and psoriasis, although where it will be positioned amidst other clinically available advanced therapies in UC requires further study.
瑞莎珠单抗（RZB）是一种重组人源化IgG单克隆抗体，通过与p19亚基的高亲和力结合选择性抑制白细胞介素（IL）-23。RZB于2022年被批准用于治疗克罗恩病（CD），并于2024年6月在美国获得溃疡性结肠炎（UC）的监管批准。
我们将研究目前可用的UC治疗方法，概述IL-23通路，讨论RZB在UC中的现有试验数据，并评论RZB如何适应目前的UC治疗模式以及该领域的未来方向。
RZB似乎是一种有效的药物，可用于诱导和维持初治及难治性UC患者的缓解，且安全性良好。对IL-23的选择性阻断在疗效上已显示出相对于联合抑制IL-12/23治疗其他疾病（如CD和银屑病）的潜在优势，尽管在UC中它与其他临床可用的先进疗法相比处于何种地位仍需进一步研究。
